Healio spoke with Matthew S. Davids, MD, about a recent study comparing continuous treatment with a Bruton tyrosine kinase inhibitor with time-limited venetoclax-based therapy for chronic lymphocytic ...
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...
Lilly Endowment Community Scholars are "known for their community involvement, academic achievement, character, and ...
Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...
The new "triple agonist" weight loss medication called retatrutide can help people lose an average of 28.7 percent of ...
In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter rotation trade continues to gather steam during the last whole trading week ...
Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...
The Brown County Community Foundation is pleased to announce the recipient of the 2026 Lilly Endowment Community Scholarship ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback